news

AKT degrader may become a new, effective treatment for many cancers

Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.

Cancer and DNA

A team of scientists at the Mount Sinai Hospital, US, have developed a therapeutic agent that displays high effectiveness in vitro at inhibiting tumour growth. The findings indicate that pharmacological degradation of AKT could be a viable treatment for cancers with mutations in certain genes in the future.

The novel therapy is an engineered molecule called MS21 that causes the degradation of AKT, a cancer gene that encodes an enzyme that is frequently activated in cancer cells to stimulate tumour growth. “Our study lays a solid foundation for the clinical development of an AKT degrader for the treatment of human cancers with certain gene mutations,” said Ramon Parsons, Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. “Examination of 44,000 human cancers identified that 19 percent of tumours have at least one of these mutations, suggesting that a large population of cancer patients could benefit from therapy with an AKT degrader such as MS21.”

MS21 was tested in human cancer-derived cell lines and the researchers are looking to develop MS21 for clinical trials. “Translating these findings into effective cancer therapies for patients is a high priority because the mutations and the resulting cancer-driving pathways that we lay out in this study are arguably the most commonly activated pathways in human cancer, but this effort has proven to be particularly challenging,” added Professor Jian Jin, Director of the Mount Sinai Center for Therapeutics Discovery. “We look forward to an opportunity to develop this molecule into a therapy that is ready to be studied in clinical trials.”

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

The team’s findings were published in Cancer Discovery.

Leave a Reply

Your email address will not be published. Required fields are marked *